今年七月，美国食品药品监督管理局的专家小组就已经因为包括心悸在内的安全问题建议撤销Vivus公司生产的减肥药Qnexa。
In July, the FDA's expert panel recommended against another proposed diet drug, Qnexa, made by Vivus inc., because of safety issues that included heart palpitations.
对于缓解公众的焦虑，此措施和2007年国家食品药品监督管理局前领导人因受贿乱开安全合格证而判处死刑相比，并没多大作用。
It appears to have done no more to alleviate public anxiety than did the execution in 2007 of a former head of the State Food and Drug Administration for taking bribes to certify products as safe.
美国食品药品监督管理局(FDA)于今日发布了上述安全通告，并提醒医护人员，新旧两种肝素制剂将会同时存在一段时间。
The Food and Drug Administration (FDA) issued the safety communication today and is warning healthcare professionals that both the old and new formulations of heparin will be available for some time.
应用推荐